|Former: Atención Farmacéutica|
|Journal edited by Rasgo Editorial since 1983|
Manuela Velázquez Prieto
EDITOR IN CHIEF
Jaime E. Poquet Jornet
Tomás Casasín Edo
Virginia Hernández Corredoira
Ramón Jódar Masanés
Juan Carlos Juárez Giménez
Volume 19 - Issue 3, May-June 2017
ANEMIA IN CANCER PATIENTS WITH RENAL FAILURE: A DOUBLE TROUBLE
GALLEGO MUÑOZ CRISTÓBAL, FERREIRA ALFAYA FRANCISCO JAVIER, GUERRERO NAVARRO NIEVES
Introduction: Anemia is a common complication of cancer and chronic kidney disease. It is typically treated with iron substitution, erythropoiesis-stimulating agents and in refractory cases with red blood cell transfusions. However, those patients have a higher risk of cerebrovascular events and increased mortality, more in patients with previous cancer history under erythropoiesis-stimulating agents’ therapy. The aim of this review is to summarize the currently available therapeutic strategies in anemia management of those patients.
Method: An exhaustive search of the published evidence in referential data sources was performed, up to February 28, 2016.
Results: We included the evidence of principal scientific societies and observational studies, clinical trials, systematic reviews and meta-analysis.
Conclusions: Although currently there are no data on the influence of iron and erythropoiesis-stimulating agents in patients with both diseases, one can propose that second agents therapy recommendations for chronic kidney disease can be applied to this group of patients. The extension of this recommendation seems more difficult in case of iron therapy.
CANCER – CHRONIC KIDNEY DISEASE – ERYTHROPOIESIS-STIMULATING AGENTS – IRON – RENAL ANEMIA